|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase II
|
|
gptkbp:contraindication
|
active infections
severe liver impairment
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
2014-10-24
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zydelig
|
|
gptkbp:indication
|
relapsed CLL
relapsed FL
relapsed SLL
|
|
gptkbp:ingredients
|
gptkb:idelalisib
C20 H22 Cl N5 O3 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
patented
2029-10-24
|
|
gptkbp:is_atype_of
|
L01 X X40
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
|
|
gptkbp:is_used_for
|
treatment of follicular lymphoma
treatment of chronic lymphocytic leukemia
treatment of small lymphocytic lymphoma
|
|
gptkbp:legal_issue
|
Prescription only
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:packaging
|
gptkb:beer
|
|
gptkbp:products
|
gptkb:obinutuzumab
gptkb:venetoclax
gptkb:ibrutinib
gptkb:rituximab
|
|
gptkbp:research
|
ongoing clinical trials
retrospective studies
real-world evidence studies
|
|
gptkbp:scholarships
|
consult healthcare provider before use
avoid live vaccines
report signs of infection
monitor for diarrhea
|
|
gptkbp:side_effect
|
diarrhea
infections
hepatotoxicity
neutropenia
colitis
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
P I3 K pathway
|
|
gptkbp:weight
|
437.94 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
|
gptkbp:bfsLayer
|
4
|